The CXCR4-Dependent LASP1-Ago2 Interaction in Triple-Negative Breast Cancer.
Argonaute2
CXCR4
LASP1
Let-7a
triple negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Aug 2020
29 Aug 2020
Historique:
received:
11
07
2020
revised:
20
08
2020
accepted:
26
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
epublish
Résumé
The CXCR4-LASP1 axis is an emerging target in the field of breast cancer metastasis. C-X-C chemokine receptor type 4 (CXCR4) mediates directed cell migration when activated by its cognate ligand CXCL12. LIM and SH3 Protein 1 (LASP1) is a critical node in the CXCR4 signaling pathway, as its deficiency blocks CXCR4-dependent Matrigel invasion. The mechanism by which LASP1 facilitates this invasive ability of tumor cells when CXCR4 is activated is unknown. Our previous proteomics work had revealed several components of the RNA interference (RNAi) machinery as being potential LASP1 interacting proteins. Here we report that argonaute 2 (Ago2), a protein with central involvement in RNAi, associates with LASP1 in triple-negative breast cancer (TNBC) cells. We demonstrate that LASP1 co-immunoprecipitates with Ago2 endogenously in a CXCL12-dependent manner, with further confirmation of this interaction by proximity ligation assay. Furthermore, this association is specific to CXCR4 as it can be abrogated by the CXCR4 antagonist, AMD3465. By GST-pulldown approach, we identify that LASP1 directly binds to Ago2 through its LIM and SH3 domains, and that this binding is dictated by the S146 and Y171 phosphorylation sites of LASP1. Additionally, the phosphorylation status of LASP1 affected tumor suppressor microRNA (miRNA) Let-7a-guided Ago2 activity. Levels of several endogenous targets of Let-7a were found to be altered including C-C chemokine receptor type 7 (CCR7), which is another critical chemokine receptor involved in metastasis to lymph nodes. Our results suggest a novel role for the LASP1-Ago2 module in shaping the RNAi landscape, functionally impacting the invasive ability of cancer cells.
Identifiants
pubmed: 32872485
pii: cancers12092455
doi: 10.3390/cancers12092455
pmc: PMC7564666
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R21 CA202176
Pays : United States
Organisme : NCI NIH HHS
ID : R21CA202176
Pays : United States
Organisme : Ohio Cancer Research Associates
ID : 5117
Organisme : University of Toledo
ID : F110796
Références
Mech Dev. 2000 Mar 1;91(1-2):5-17
pubmed: 10704826
Thromb Haemost. 2009 Sep;102(3):520-8
pubmed: 19718473
Exp Cell Res. 2011 Mar 10;317(5):575-89
pubmed: 21223965
Biosci Rep. 2017 May 17;37(3):
pubmed: 28381518
Cancers (Basel). 2020 Aug 21;12(9):
pubmed: 32825729
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Biochem Pharmacol. 2009 Oct 15;78(8):993-1000
pubmed: 19540208
J Exp Med. 2008 Apr 14;205(4):777-83
pubmed: 18378795
Oncogene. 2013 Apr 18;32(16):2107-13
pubmed: 22665060
Cell Rep. 2014 Jan 16;6(1):211-21
pubmed: 24388755
J Cell Biol. 2004 May 10;165(3):421-32
pubmed: 15138294
Mol Cell. 2004 Jul 23;15(2):185-97
pubmed: 15260970
Biochem Pharmacol. 2005 Sep 1;70(5):752-61
pubmed: 16011832
FEBS Lett. 2017 Feb;591(4):636-645
pubmed: 28117895
Clin Cancer Res. 2005 Aug 15;11(16):5686-93
pubmed: 16115904
Methods Enzymol. 2009;460:315-30
pubmed: 19446732
Nucleic Acids Res. 2011 Jul;39(13):5682-91
pubmed: 21427083
PLoS One. 2010 Apr 19;5(4):e10050
pubmed: 20419088
Mol Med. 1998 Oct;4(10):675-87
pubmed: 9848085
J Biol Chem. 2003 May 2;278(18):15601-7
pubmed: 12571245
Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52
pubmed: 25378301
Oncogene. 2016 Mar 3;35(9):1122-33
pubmed: 25982273
Oncogene. 2016 Apr 7;35(14):1822-31
pubmed: 26165837
Int J Oncol. 2015 May;46(5):1901-12
pubmed: 25760690
Genomics. 1995 Aug 10;28(3):367-76
pubmed: 7490069
Cancer Cell. 2004 Jul;6(1):17-32
pubmed: 15261139
RNA. 2005 Nov;11(11):1640-7
pubmed: 16177138
Genes Dev. 2011 Aug 15;25(16):1686-701
pubmed: 21852534
J Cell Physiol. 2015 Jan;230(1):27-42
pubmed: 24913264
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
Nature. 2010 Jun 3;465(7298):584-9
pubmed: 20424607
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Oncogene. 2013 Jul 4;32(27):3306-10
pubmed: 22926517
FASEB J. 2006 Jun;20(8):1218-20
pubmed: 16641196
Cell Rep. 2017 Jul 5;20(1):173-187
pubmed: 28683311
Nat Struct Mol Biol. 2012 Oct;19(10):998-1004
pubmed: 22961379
Oncotarget. 2015 Jan 1;6(1):26-42
pubmed: 25622104
Tumour Biol. 2016 Apr;37(4):5001-11
pubmed: 26537584
Mol Cell Biol. 2009 Dec;29(23):6220-31
pubmed: 19797087
Biochem Biophys Res Commun. 2004 Nov 5;324(1):308-16
pubmed: 15465019
Biochem J. 2015 Feb 1;465(3):383-93
pubmed: 25358683
Wiley Interdiscip Rev RNA. 2016 Sep;7(5):637-60
pubmed: 27184117
Nat Commun. 2017 Mar 07;8:14483
pubmed: 28266545
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Front Oncol. 2019 Apr 24;9:284
pubmed: 31106142
Cell. 2007 Dec 14;131(6):1097-108
pubmed: 18083100
Mol Biol Cell. 2016 Mar 9;:
pubmed: 26960796
Cell. 2018 May 3;173(4):879-893.e13
pubmed: 29681456
Mol Cell. 2011 Oct 7;44(1):120-33
pubmed: 21981923
Curr Biol. 1993 Jul 1;3(7):434-42
pubmed: 15335710
PLoS One. 2011;6(5):e20680
pubmed: 21655198
Med Oncol. 2013 Mar;30(1):411
pubmed: 23292834
Cell. 2005 Nov 18;123(4):631-40
pubmed: 16271387
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Oncogene. 2007 Oct 25;26(49):6997-7005
pubmed: 17486065
Cancer Metastasis Rev. 2010 Dec;29(4):709-22
pubmed: 20839032
Nat Struct Mol Biol. 2007 Oct;14(10):897-903
pubmed: 17891150
PLoS One. 2013 Dec 11;8(12):e83083
pubmed: 24349438
J Biol Chem. 2004 May 7;279(19):20401-10
pubmed: 15004028
RNA. 2008 Jun;14(6):1012-7
pubmed: 18426918
Cancer. 2008 Nov 15;113(10):2638-45
pubmed: 18833576
Int J Oncol. 2015;46(6):2526-34
pubmed: 25846193
Exp Cell Res. 2006 Apr 15;312(7):974-82
pubmed: 16430883
Cells. 2020 Feb 14;9(2):
pubmed: 32075106
Cell Death Differ. 2009 May;16(5):664-73
pubmed: 19136936
J Biol Chem. 2007 Sep 14;282(37):27354-65
pubmed: 17599916
Breast Cancer Res. 2012 Jan 18;14(1):R14
pubmed: 22251626
FEBS Lett. 1995 Oct 16;373(3):245-9
pubmed: 7589475
Clin Cancer Res. 2010 Jun 1;16(11):2927-31
pubmed: 20484021
Nat Struct Mol Biol. 2005 Apr;12(4):340-9
pubmed: 15800637
Cancer. 2012 Nov 15;118(22):5463-72
pubmed: 22544643
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
PLoS Genet. 2014 Feb 27;10(2):e1004177
pubmed: 24586203
Genes Dev. 2006 Jul 15;20(14):1885-98
pubmed: 16815998
Front Oncol. 2018 Sep 21;8:391
pubmed: 30298118
PLoS One. 2013;8(3):e58426
pubmed: 23484027
Gene. 2018 Dec 30;679:232-240
pubmed: 30201337
Gene. 1998 Jan 30;207(2):171-5
pubmed: 9511759
J Biol Chem. 2009 Jul 3;284(27):17897-901
pubmed: 19342379
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10655-9
pubmed: 7938009
Oncotarget. 2016 Feb 2;7(5):5702-14
pubmed: 26744318
Br J Cancer. 2010 May 25;102(11):1645-53
pubmed: 20461080
Nature. 1996 Aug 29;382(6594):829-33
pubmed: 8752280
Nat Struct Mol Biol. 2006 Sep;13(9):787-92
pubmed: 16936728
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
RNA. 2005 Apr;11(4):459-69
pubmed: 15703439
Clin Cancer Res. 2008 Dec 1;14(23):7804-12
pubmed: 19047108
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Mol Cell. 2019 Aug 22;75(4):741-755.e11
pubmed: 31324449
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925